
Cryo-Cell International ( ($CCEL) ) has shared an update. On October 27, 2026, Cryo-Cell International, Inc. held its Annual Meeting of Stockholders, where shareholders voted on board composition, auditor ratification,
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CCEL | Cryo-Cell International | 4.63 | 0.55 | 13.48% |
| Name | Price | % Change | |
|---|---|---|---|
| $4.63 | +13.48% |

Cryo-Cell International ( ($CCEL) ) has shared an update. On October 27, 2026, Cryo-Cell International, Inc. held its Annual Meeting of Stockholders, where shareholders voted on board composition, auditor ratification,

Cryo-Cell International (CCEL) is scheduled to report 3rd quarter earnings on 10/09/2026. Regarding Q3 estimates, Wall Street analysts expect Cryo-Cell International to post earnings of $0.03 per share. Revenue expectations

Cryo-Cell International ( ($CCEL) ) just unveiled an update. Cryo-Cell International’s board of directors has scheduled the company’s 2026 Annual Meeting of Stockholders for October 27, 2026, and set September

Reports Q2 revenue $7.8M vs $7.9M last year. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks

Cryo-Cell International (CCEL) is scheduled to report 2nd quarter earnings on 07/09/2026. Regarding Q2 estimates, Wall Street analysts expect Cryo-Cell International to post earnings of $0.00 per share. Revenue expectations

Cryo-Cell (CCEL) announced that the NYSE American has accepted the company’s previously submitted plan to regain compliance with continued listing standards. As previously disclosed on March 12, the company was

Cryo-Cell International ( ($CCEL) ) has issued an update. On May 6, 2026, Cryo-Cell International received notice that NYSE Regulation had accepted its plan to regain compliance with NYSE American’s

Cryo-Cell International (CCEL) has disclosed a new risk, in the Regulation category. Cryo-Cell International faces uncertainty as NYSE American evaluates its Plan of Compliance, with no assurance that the plan

Reports Q1 revenue $7.68M vs. $7.97M last year. The company said, “The revenues for the first quarter of fiscal 2026 were $7.68 million compared to $7.97 million for the first

The latest announcement is out from Cryo-Cell International ( ($CCEL) ). On March 9, 2026, Cryo-Cell International, Inc. received notice from NYSE American that it was not in compliance with
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Reiterated | Apr 16, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 26, 2027TBA | $36.69M | ― | ― | 0.02 | -18.33 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.